APA (7th ed.) Citation

DC, Z., C, T., K, A., AE, B., D, S., A, A., . . . H, G. (2025). Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results. Critical reviews in oncology/hematology, 208, 104635. https://doi.org/10.1016/j.critrevonc.2025.104635

Chicago Style (17th ed.) Citation

DC, Ziogas, Theocharopoulos C, Aravantinou K, Boukouris AE, Stefanou D, Anastasopoulou A, Lialios PP, Lyrarakis G, and Gogas H. "Clinical Benefit of Immune Checkpoint Inhibitors in Elderly Cancer Patients: Current Evidence from Immunosenescence Pathophysiology to Clinical Trial Results." Critical Reviews in Oncology/hematology 208 (2025): 104635. https://doi.org/10.1016/j.critrevonc.2025.104635.

MLA (9th ed.) Citation

DC, Ziogas, et al. "Clinical Benefit of Immune Checkpoint Inhibitors in Elderly Cancer Patients: Current Evidence from Immunosenescence Pathophysiology to Clinical Trial Results." Critical Reviews in Oncology/hematology, vol. 208, 2025, p. 104635, https://doi.org/10.1016/j.critrevonc.2025.104635.